SCHEMBL23535201

SCHEMBL23535201

CC1CC1c1cnc2nc(C(=O)O)cn2c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.38
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
KDM4E B2RXH2 2/20 0.33
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
MAP4K1 Q92918 1/20 0.31
HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23534192 0.82 KDM4E (0.44) RXFP1PTGS1PTGS2KDM4EGLA
SCHEMBL23534306 0.81 RXFP1 (0.33) RXFP1PTGS1PTGS2KDM4EGLA
SCHEMBL23535525 0.78 PTGS1 (0.36) RXFP1PTGS1PTGS2KDM4EGLA
SCHEMBL3499989 0.75 RXFP1 (0.50) RXFP1PTGS1PTGS2KDM4EHTT
SCHEMBL23553891 0.75 RXFP1 (0.43) RXFP1PTGS1PTGS2KDM4ETDP1
Bromide SCHEMBL2731255 0.74 RXFP1 (0.49) RXFP1PTGS1PTGS2KDM4EHTT
SCHEMBL2326296 0.73 PTGS1 (0.41) RXFP1PTGS1PTGS2KDM4EADORA2A
SCHEMBL23571979 0.73 PTGS1 (0.41) RXFP1PTGS1PTGS2KDM4EHIF1A
SCHEMBL21033716 0.71 CCNC (0.46)
SCHEMBL2723092 0.70 KMT2A (0.39) RXFP1PTGS1PTGS2KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 US disclosed
US-20230114091-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-13 US disclosed
US-20230108114-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-06 US disclosed
EP-4076459-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 EP disclosed
WO-2021126728-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126728-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114091-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RXFP1 2368/4885PTGS1 1716/4885PTGS2 2255/4885
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 RXFP1 723/4885PTGS1 3174/4885PTGS2 3718/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 RXFP1 2368/4885PTGS1 1716/4885PTGS2 2255/4885
US-20230108114-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RXFP1 2526/4885PTGS1 1796/4885PTGS2 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.